The dexamethasone suppression test as a monitor of clinical recovery
To evaluate the dexamethasone suppression test (DST) as an aid in monitoring clinical recovery, the authors evaluated 127 outpatients with major depression who received the DST during depression and after clinical recovery. Although DST response varied among the 73 patients who met the Research Diag...
Gespeichert in:
| Veröffentlicht in: | The American journal of psychiatry 1987-01, Vol.144 (1), p.30-35 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 35 |
|---|---|
| container_issue | 1 |
| container_start_page | 30 |
| container_title | The American journal of psychiatry |
| container_volume | 144 |
| creator | PESELOW, E. D BAXTER, N FIEVE, R. R BAROUCHE, F |
| description | To evaluate the dexamethasone suppression test (DST) as an aid in
monitoring clinical recovery, the authors evaluated 127 outpatients with
major depression who received the DST during depression and after clinical
recovery. Although DST response varied among the 73 patients who met the
Research Diagnostic Criteria for definite endogenous depression, their mean
postdexamethasone plasma cortisol level was significantly higher during
depression than after recovery. However, the DST's utility in monitoring
long-term outcome was not great, as there was a high chance of remaining
stable for 6 months after recovery regardless of cortisol value during
depression or after recovery. |
| doi_str_mv | 10.1176/ajp.144.1.30 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77367759</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1310603567</sourcerecordid><originalsourceid>FETCH-LOGICAL-a404t-b91d4fb1284c821026b1e3baf48be8aa399feb999587b7263069a9e99b5377063</originalsourceid><addsrcrecordid>eNp10Mtr3DAQBnBREpLN49ZrQaQlEKg3elmyjiWPJhDoJYHcxMg7Jl5sy5Xs0Pz3VdgllNCcxDA_Pg0fIZ85W3Ju9DmsxyVXasmXkn0iC17KsjBCVDtkwRgThS3l4z45SGmdRyaN2CN70lhbSb0gl_dPSFf4B3qcniCFAWmaxzFiSm0Y6IRpopAo0D4M7RQiDQ2tu3Zoa-hoxDo8Y3w5IrsNdAmPt-8hebi-ur-4Ke5-_by9-HFXgGJqKrzlK9V4LipVV4IzoT1H6aFRlccKQFrboLfWlpXxRmjJtAWL1vpSGsO0PCSnm9wxht9zPs31baqx62DAMCdnjNTGlDbDk3dwHeY45NucEEzlrFJl9PUjxCVnmslSm6y-b1QdQ0oRGzfGtof44jhzr_273L_L_TvuJMv8yzZ09j2u3vC28Lz_tt1DyhU2EYa6TW-sEkJoxjM72zAYx_afu_735V-TDpiu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1310603567</pqid></control><display><type>article</type><title>The dexamethasone suppression test as a monitor of clinical recovery</title><source>MEDLINE</source><source>Psychiatry Legacy Collection Online Journals 1844-1996</source><source>Periodicals Index Online</source><creator>PESELOW, E. D ; BAXTER, N ; FIEVE, R. R ; BAROUCHE, F</creator><creatorcontrib>PESELOW, E. D ; BAXTER, N ; FIEVE, R. R ; BAROUCHE, F</creatorcontrib><description>To evaluate the dexamethasone suppression test (DST) as an aid in
monitoring clinical recovery, the authors evaluated 127 outpatients with
major depression who received the DST during depression and after clinical
recovery. Although DST response varied among the 73 patients who met the
Research Diagnostic Criteria for definite endogenous depression, their mean
postdexamethasone plasma cortisol level was significantly higher during
depression than after recovery. However, the DST's utility in monitoring
long-term outcome was not great, as there was a high chance of remaining
stable for 6 months after recovery regardless of cortisol value during
depression or after recovery.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/ajp.144.1.30</identifier><identifier>PMID: 3799836</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>Adult ; Ambulatory Care ; Antidepressive Agents - therapeutic use ; Biological and medical sciences ; Depressive Disorder - blood ; Depressive Disorder - diagnosis ; Depressive Disorder - drug therapy ; Dexamethasone ; Female ; Humans ; Hydrocortisone - blood ; Male ; Medical sciences ; Mental depression ; Miscellaneous ; Outcome and Process Assessment (Health Care) ; Probability ; Prospective Studies ; Psychiatric Status Rating Scales ; Psychiatry ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Recurrence ; Social research ; Techniques and methods</subject><ispartof>The American journal of psychiatry, 1987-01, Vol.144 (1), p.30-35</ispartof><rights>1987 INIST-CNRS</rights><rights>Copyright American Psychiatric Association Jan 1987</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a404t-b91d4fb1284c821026b1e3baf48be8aa399feb999587b7263069a9e99b5377063</citedby><cites>FETCH-LOGICAL-a404t-b91d4fb1284c821026b1e3baf48be8aa399feb999587b7263069a9e99b5377063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/ajp.144.1.30$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/ajp.144.1.30$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,777,781,2846,4010,21610,27850,27904,27905,27906,77540,77541</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8222601$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3799836$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PESELOW, E. D</creatorcontrib><creatorcontrib>BAXTER, N</creatorcontrib><creatorcontrib>FIEVE, R. R</creatorcontrib><creatorcontrib>BAROUCHE, F</creatorcontrib><title>The dexamethasone suppression test as a monitor of clinical recovery</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>To evaluate the dexamethasone suppression test (DST) as an aid in
monitoring clinical recovery, the authors evaluated 127 outpatients with
major depression who received the DST during depression and after clinical
recovery. Although DST response varied among the 73 patients who met the
Research Diagnostic Criteria for definite endogenous depression, their mean
postdexamethasone plasma cortisol level was significantly higher during
depression than after recovery. However, the DST's utility in monitoring
long-term outcome was not great, as there was a high chance of remaining
stable for 6 months after recovery regardless of cortisol value during
depression or after recovery.</description><subject>Adult</subject><subject>Ambulatory Care</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Depressive Disorder - blood</subject><subject>Depressive Disorder - diagnosis</subject><subject>Depressive Disorder - drug therapy</subject><subject>Dexamethasone</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrocortisone - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental depression</subject><subject>Miscellaneous</subject><subject>Outcome and Process Assessment (Health Care)</subject><subject>Probability</subject><subject>Prospective Studies</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Recurrence</subject><subject>Social research</subject><subject>Techniques and methods</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>K30</sourceid><recordid>eNp10Mtr3DAQBnBREpLN49ZrQaQlEKg3elmyjiWPJhDoJYHcxMg7Jl5sy5Xs0Pz3VdgllNCcxDA_Pg0fIZ85W3Ju9DmsxyVXasmXkn0iC17KsjBCVDtkwRgThS3l4z45SGmdRyaN2CN70lhbSb0gl_dPSFf4B3qcniCFAWmaxzFiSm0Y6IRpopAo0D4M7RQiDQ2tu3Zoa-hoxDo8Y3w5IrsNdAmPt-8hebi-ur-4Ke5-_by9-HFXgGJqKrzlK9V4LipVV4IzoT1H6aFRlccKQFrboLfWlpXxRmjJtAWL1vpSGsO0PCSnm9wxht9zPs31baqx62DAMCdnjNTGlDbDk3dwHeY45NucEEzlrFJl9PUjxCVnmslSm6y-b1QdQ0oRGzfGtof44jhzr_273L_L_TvuJMv8yzZ09j2u3vC28Lz_tt1DyhU2EYa6TW-sEkJoxjM72zAYx_afu_735V-TDpiu</recordid><startdate>19870101</startdate><enddate>19870101</enddate><creator>PESELOW, E. D</creator><creator>BAXTER, N</creator><creator>FIEVE, R. R</creator><creator>BAROUCHE, F</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>HAWNG</scope><scope>HBMBR</scope><scope>IBDFT</scope><scope>K30</scope><scope>PAAUG</scope><scope>PAWHS</scope><scope>PAWZZ</scope><scope>PAXOH</scope><scope>PBHAV</scope><scope>PBQSW</scope><scope>PBYQZ</scope><scope>PCIWU</scope><scope>PCMID</scope><scope>PCZJX</scope><scope>PDGRG</scope><scope>PDWWI</scope><scope>PETMR</scope><scope>PFVGT</scope><scope>PGXDX</scope><scope>PIHIL</scope><scope>PISVA</scope><scope>PJCTQ</scope><scope>PJTMS</scope><scope>PLCHJ</scope><scope>PMHAD</scope><scope>PNQDJ</scope><scope>POUND</scope><scope>PPLAD</scope><scope>PQAPC</scope><scope>PQCAN</scope><scope>PQCMW</scope><scope>PQEME</scope><scope>PQHKH</scope><scope>PQMID</scope><scope>PQNCT</scope><scope>PQNET</scope><scope>PQSCT</scope><scope>PQSET</scope><scope>PSVJG</scope><scope>PVMQY</scope><scope>PZGFC</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>19870101</creationdate><title>The dexamethasone suppression test as a monitor of clinical recovery</title><author>PESELOW, E. D ; BAXTER, N ; FIEVE, R. R ; BAROUCHE, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a404t-b91d4fb1284c821026b1e3baf48be8aa399feb999587b7263069a9e99b5377063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Adult</topic><topic>Ambulatory Care</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Depressive Disorder - blood</topic><topic>Depressive Disorder - diagnosis</topic><topic>Depressive Disorder - drug therapy</topic><topic>Dexamethasone</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrocortisone - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental depression</topic><topic>Miscellaneous</topic><topic>Outcome and Process Assessment (Health Care)</topic><topic>Probability</topic><topic>Prospective Studies</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Recurrence</topic><topic>Social research</topic><topic>Techniques and methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PESELOW, E. D</creatorcontrib><creatorcontrib>BAXTER, N</creatorcontrib><creatorcontrib>FIEVE, R. R</creatorcontrib><creatorcontrib>BAROUCHE, F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Periodicals Index Online Segment 13</collection><collection>Periodicals Index Online Segment 14</collection><collection>Periodicals Index Online Segment 27</collection><collection>Periodicals Index Online</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - West</collection><collection>Primary Sources Access (Plan D) - International</collection><collection>Primary Sources Access & Build (Plan A) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Midwest</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Northeast</collection><collection>Primary Sources Access (Plan D) - Southeast</collection><collection>Primary Sources Access (Plan D) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Southeast</collection><collection>Primary Sources Access (Plan D) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - UK / I</collection><collection>Primary Sources Access (Plan D) - Canada</collection><collection>Primary Sources Access (Plan D) - EMEALA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - International</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - International</collection><collection>Primary Sources Access (Plan D) - West</collection><collection>Periodicals Index Online Segments 1-50</collection><collection>Primary Sources Access (Plan D) - APAC</collection><collection>Primary Sources Access (Plan D) - Midwest</collection><collection>Primary Sources Access (Plan D) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Canada</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - EMEALA</collection><collection>Primary Sources Access & Build (Plan A) - APAC</collection><collection>Primary Sources Access & Build (Plan A) - Canada</collection><collection>Primary Sources Access & Build (Plan A) - West</collection><collection>Primary Sources Access & Build (Plan A) - EMEALA</collection><collection>Primary Sources Access (Plan D) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - Midwest</collection><collection>Primary Sources Access & Build (Plan A) - North Central</collection><collection>Primary Sources Access & Build (Plan A) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - Southeast</collection><collection>Primary Sources Access (Plan D) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - APAC</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - MEA</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PESELOW, E. D</au><au>BAXTER, N</au><au>FIEVE, R. R</au><au>BAROUCHE, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The dexamethasone suppression test as a monitor of clinical recovery</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>1987-01-01</date><risdate>1987</risdate><volume>144</volume><issue>1</issue><spage>30</spage><epage>35</epage><pages>30-35</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>To evaluate the dexamethasone suppression test (DST) as an aid in
monitoring clinical recovery, the authors evaluated 127 outpatients with
major depression who received the DST during depression and after clinical
recovery. Although DST response varied among the 73 patients who met the
Research Diagnostic Criteria for definite endogenous depression, their mean
postdexamethasone plasma cortisol level was significantly higher during
depression than after recovery. However, the DST's utility in monitoring
long-term outcome was not great, as there was a high chance of remaining
stable for 6 months after recovery regardless of cortisol value during
depression or after recovery.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>3799836</pmid><doi>10.1176/ajp.144.1.30</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-953X |
| ispartof | The American journal of psychiatry, 1987-01, Vol.144 (1), p.30-35 |
| issn | 0002-953X 1535-7228 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77367759 |
| source | MEDLINE; Psychiatry Legacy Collection Online Journals 1844-1996; Periodicals Index Online |
| subjects | Adult Ambulatory Care Antidepressive Agents - therapeutic use Biological and medical sciences Depressive Disorder - blood Depressive Disorder - diagnosis Depressive Disorder - drug therapy Dexamethasone Female Humans Hydrocortisone - blood Male Medical sciences Mental depression Miscellaneous Outcome and Process Assessment (Health Care) Probability Prospective Studies Psychiatric Status Rating Scales Psychiatry Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Recurrence Social research Techniques and methods |
| title | The dexamethasone suppression test as a monitor of clinical recovery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A33%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20dexamethasone%20suppression%20test%20as%20a%20monitor%20of%20clinical%20recovery&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=PESELOW,%20E.%20D&rft.date=1987-01-01&rft.volume=144&rft.issue=1&rft.spage=30&rft.epage=35&rft.pages=30-35&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/ajp.144.1.30&rft_dat=%3Cproquest_cross%3E1310603567%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1310603567&rft_id=info:pmid/3799836&rfr_iscdi=true |